BR112016014760A2 - composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína - Google Patents

composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína

Info

Publication number
BR112016014760A2
BR112016014760A2 BR112016014760A BR112016014760A BR112016014760A2 BR 112016014760 A2 BR112016014760 A2 BR 112016014760A2 BR 112016014760 A BR112016014760 A BR 112016014760A BR 112016014760 A BR112016014760 A BR 112016014760A BR 112016014760 A2 BR112016014760 A2 BR 112016014760A2
Authority
BR
Brazil
Prior art keywords
methods
cell
compound
modulating
activity
Prior art date
Application number
BR112016014760A
Other languages
English (en)
Inventor
Bor-Jen Liau Brian
Efrem Pelish Henry
Young Ahn Jae
Ramharter Juergen
D Shair Matthew
Original Assignee
Harvard College
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Harvard College filed Critical Harvard College
Publication of BR112016014760A2 publication Critical patent/BR112016014760A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/22—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains four or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/26—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against hormones ; against hormone releasing or inhibiting factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

são fornecidos aqui compostos da fórmula (a), (b), (c), (d) e (e), (a), (c) (b), (d), (e) sais farmaceuticamente aceitáveis, sais de amina quaternários e n-óxidos destes farmaceuticamente aceitáveis e composições farmacêuticas dos mesmos. os compostos da fórmula (a), (b), (c), (d) e (e) são considerados úteis como terapêuticos para tratar uma variedade ampla de condições, por exemplo, que incluem, mas não se limitam a, condições associadas com a angiogênese e com atividade de cinase cdk8 e/ou cdk19. ainda são fornecidos métodos de inibir atividade de cinase cdk8 e/ou cdk19, métodos de modular o trajeto de ß-catenina, métodos de modular a atividade de stat1, métodos de modular o trajeto de tgfß/bmp, métodos de modular a atividade de hif-1-alfa em uma célula e métodos de aumentar a expressão de bim para induzir a apoptose, usando-se um composto da fórmula (a), (b), (c), (d) ou (e). ainda são fornecidos mutantes pontuais cdk8 e cdk19 e métoros de uso dos mesmos.
BR112016014760A 2013-12-24 2014-12-24 composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína BR112016014760A2 (pt)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201361920674P 2013-12-24 2013-12-24
US201461935240P 2014-02-03 2014-02-03
US201461993329P 2014-05-15 2014-05-15
PCT/US2014/072365 WO2015100420A1 (en) 2013-12-24 2014-12-24 Cortistatin analogues and syntheses and uses thereof

Publications (1)

Publication Number Publication Date
BR112016014760A2 true BR112016014760A2 (pt) 2017-12-12

Family

ID=52350382

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016014760A BR112016014760A2 (pt) 2013-12-24 2014-12-24 composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína

Country Status (30)

Country Link
US (3) US9994582B2 (pt)
EP (2) EP3505521A1 (pt)
JP (2) JP6494631B2 (pt)
KR (1) KR20160101162A (pt)
CN (2) CN110183461A (pt)
AP (1) AP2016009324A0 (pt)
AU (2) AU2014369834B2 (pt)
BR (1) BR112016014760A2 (pt)
CA (1) CA2934819A1 (pt)
CL (1) CL2016001631A1 (pt)
CR (1) CR20160291A (pt)
DO (1) DOP2016000158A (pt)
EA (2) EA030907B1 (pt)
EC (1) ECSP16062174A (pt)
ES (1) ES2709480T3 (pt)
GT (1) GT201600135A (pt)
IL (1) IL246390A0 (pt)
MD (1) MD20160089A2 (pt)
MX (1) MX361652B (pt)
MY (1) MY180383A (pt)
NI (1) NI201600089A (pt)
PE (1) PE20161405A1 (pt)
PH (1) PH12016501258A1 (pt)
RU (1) RU2016126503A (pt)
SA (1) SA516371410B1 (pt)
SG (2) SG10201808151RA (pt)
SV (1) SV2016005234A (pt)
TN (1) TN2016000240A1 (pt)
WO (1) WO2015100420A1 (pt)
ZA (1) ZA201603894B (pt)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PE20161405A1 (es) 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos
AU2015210833B2 (en) 2014-02-03 2019-01-03 Vitae Pharmaceuticals, Llc Dihydropyrrolopyridine inhibitors of ROR-gamma
US9663515B2 (en) 2014-11-05 2017-05-30 Vitae Pharmaceuticals, Inc. Dihydropyrrolopyridine inhibitors of ROR-gamma
RU2017142394A (ru) * 2015-05-08 2019-06-10 Президент Энд Феллоус Оф Гарвард Колледж Целевой отбор пациентов для лечения производными кортистатина
EP3294298A4 (en) 2015-05-08 2018-10-17 President and Fellows of Harvard College Cortistatin analogues, syntheses, and uses thereof
EP3316889A4 (en) * 2015-07-01 2018-11-14 President and Fellows of Harvard College Cortistatin analogues and syntheses and uses thereof
EP3331876B1 (en) 2015-08-05 2020-10-07 Vitae Pharmaceuticals, LLC Modulators of ror-gamma
MX2018006223A (es) 2015-11-20 2018-12-19 Vitae Pharmaceuticals Inc Moduladores de ror-gamma.
EP3394038A4 (en) * 2015-12-23 2019-08-21 President and Fellows of Harvard College TARGETED PATIENT SELECTION FOR TREATMENT WITH SPECIFIC CORTISTANTIDE DERIVATIVES
SG11201805092WA (en) * 2015-12-23 2018-07-30 Harvard College Cortistatin analogs and uses thereof
TW202220968A (zh) 2016-01-29 2022-06-01 美商維它藥物有限責任公司 ＲＯＲ－γ調節劑
MX2018009998A (es) * 2016-02-19 2018-12-10 Harvard College Analogos de cortistatina.
US11285144B2 (en) 2016-08-03 2022-03-29 The Broad Institute, Inc. Use of CDK8 inhibitors to treat diseases of inflammation and autoimmunity
US11578067B2 (en) 2017-01-30 2023-02-14 Kyoto University Compound, and method for producing regulatory T cells
CN107028956A (zh) * 2017-03-06 2017-08-11 刘杰 一种治疗经期抑郁症的药物组合物
EP3658555A1 (en) 2017-07-24 2020-06-03 Vitae Pharmaceuticals, LLC Inhibitors of ror
WO2019018975A1 (en) 2017-07-24 2019-01-31 Vitae Pharmaceuticals, Inc. INHIBITORS OF ROR GAMMA
WO2019068613A1 (en) 2017-10-02 2019-04-11 Boehringer Ingelheim International Gmbh NOVEL [1,6] NAPHTHYRIDINE COMPOUNDS AND DERIVATIVES AS CDK8 / CDK19 INHIBITORS
CN113677341A (zh) * 2019-02-01 2021-11-19 南卡罗莱纳大学 双环吡啶组合物及其用于癌症治疗的方法
CN118056007A (zh) 2021-09-27 2024-05-17 国立大学法人京都大学 用于生产t细胞的方法

Family Cites Families (86)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2886589A (en) 1957-08-05 1959-05-12 Merck & Co Inc 8-methyl-5-oxyphenyl hexahydroindan compounds
US4270537A (en) 1979-11-19 1981-06-02 Romaine Richard A Automatic hypodermic syringe
US4596556A (en) 1985-03-25 1986-06-24 Bioject, Inc. Hypodermic injection apparatus
US4863457A (en) 1986-11-24 1989-09-05 Lee David A Drug delivery device
CA1283827C (en) 1986-12-18 1991-05-07 Giorgio Cirelli Appliance for injection of liquid formulations
GB8704027D0 (en) 1987-02-20 1987-03-25 Owen Mumford Ltd Syringe needle combination
US4940460A (en) 1987-06-19 1990-07-10 Bioject, Inc. Patient-fillable and non-invasive hypodermic injection device assembly
US4941880A (en) 1987-06-19 1990-07-17 Bioject, Inc. Pre-filled ampule and non-invasive hypodermic injection device assembly
US4790824A (en) 1987-06-19 1988-12-13 Bioject, Inc. Non-invasive hypodermic injection device
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
US5339163A (en) 1988-03-16 1994-08-16 Canon Kabushiki Kaisha Automatic exposure control device using plural image plane detection areas
FR2638359A1 (fr) 1988-11-03 1990-05-04 Tino Dalto Guide de seringue avec reglage de la profondeur de penetration de l'aiguille dans la peau
US5098443A (en) 1989-03-23 1992-03-24 University Of Miami Method of implanting intraocular and intraorbital implantable devices for the controlled release of pharmacological agents
US5064413A (en) 1989-11-09 1991-11-12 Bioject, Inc. Needleless hypodermic injection device
US5312335A (en) 1989-11-09 1994-05-17 Bioject Inc. Needleless hypodermic injection device
US5185152A (en) 1990-01-10 1993-02-09 Peyman Gholam A Method and apparatus for controlled release drug delivery to the cornea and anterior chamber of the eye
US5190521A (en) 1990-08-22 1993-03-02 Tecnol Medical Products, Inc. Apparatus and method for raising a skin wheal and anesthetizing skin
US5410016A (en) 1990-10-15 1995-04-25 Board Of Regents, The University Of Texas System Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers
US5527288A (en) 1990-12-13 1996-06-18 Elan Medical Technologies Limited Intradermal drug delivery device and method for intradermal delivery of drugs
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
GB9118204D0 (en) 1991-08-23 1991-10-09 Weston Terence E Needle-less injector
SE9102652D0 (sv) 1991-09-13 1991-09-13 Kabi Pharmacia Ab Injection needle arrangement
US5328483A (en) 1992-02-27 1994-07-12 Jacoby Richard M Intradermal injection device with medication and needle guard
IL105050A0 (en) 1992-03-27 1993-07-08 Lilly Co Eli Steroid derivatives
US5383851A (en) 1992-07-24 1995-01-24 Bioject Inc. Needleless hypodermic injection device
US5569189A (en) 1992-09-28 1996-10-29 Equidyne Systems, Inc. hypodermic jet injector
US5334144A (en) 1992-10-30 1994-08-02 Becton, Dickinson And Company Single use disposable needleless injector
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
WO1995024176A1 (en) 1994-03-07 1995-09-14 Bioject, Inc. Ampule filling device
US5466220A (en) 1994-03-08 1995-11-14 Bioject, Inc. Drug vial mixing and transfer device
SE9401108D0 (sv) 1994-03-31 1994-03-31 Leiras Oy Ophthalmic composition I
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
US5599302A (en) 1995-01-09 1997-02-04 Medi-Ject Corporation Medical injection system and method, gas spring thereof and launching device using gas spring
US5730723A (en) 1995-10-10 1998-03-24 Visionary Medical Products Corporation, Inc. Gas pressured needle-less injection device and method
US5847172A (en) 1995-06-07 1998-12-08 Magainin Pharmaceuticals Inc. Certain aminosterol compounds and pharmaceutical compositions including these compounds
US5554187A (en) 1995-08-18 1996-09-10 Rizzo, Iii; Joseph Medication dispensing intra-ocular lens system
US5893397A (en) 1996-01-12 1999-04-13 Bioject Inc. Medication vial/syringe liquid-transfer apparatus
GB9607549D0 (en) 1996-04-11 1996-06-12 Weston Medical Ltd Spring-powered dispensing device
US6074872A (en) 1996-05-15 2000-06-13 The Scripps Research Institute Cortistatin: nucleic acids that encode these neuropeptides
ZA978537B (en) 1996-09-23 1998-05-12 Focal Inc Polymerizable biodegradable polymers including carbonate or dioxanone linkages.
AU5902398A (en) 1996-12-31 1998-07-31 Human Genome Sciences, Inc. Cortistatin polypeptides
US5993412A (en) 1997-05-19 1999-11-30 Bioject, Inc. Injection apparatus
IT1298087B1 (it) 1998-01-08 1999-12-20 Fiderm S R L Dispositivo per il controllo della profondita' di penetrazione di un ago, in particolare applicabile ad una siringa per iniezioni
US6632457B1 (en) 1998-08-14 2003-10-14 Incept Llc Composite hydrogel drug delivery systems
US6667299B1 (en) 2000-03-16 2003-12-23 Hollis-Eden Pharmaceuticals, Inc. Pharmaceutical compositions and treatment methods
US20030060425A1 (en) 1998-11-24 2003-03-27 Ahlem Clarence N. Immune modulation method using steroid compounds
US6291516B1 (en) 1999-01-13 2001-09-18 Curis, Inc. Regulators of the hedgehog pathway, compositions and uses related thereto
KR20020028876A (ko) 1999-04-30 2002-04-17 추후제출 스테로이드 유도체
CA2670236C (en) 1999-09-30 2012-06-05 Hollis-Eden Pharmaceuticals, Inc. Therapeutic treatment of androgen receptor driven conditions
WO2001027135A2 (en) 1999-10-13 2001-04-19 Johns Hopkins University School Of Medicine Regulators of the hedgehog pathway, compositions and uses related thereto
EP1223941B1 (en) 1999-10-25 2008-11-05 Hollis-Eden Pharmaceuticals Inc. Therapeutic treatments for blood cell deficiencies using sreroids
CN1827621A (zh) * 2000-03-31 2006-09-06 萨诺化学药物股份公司 雪花胺的新衍生物和类似物
JP2005503425A (ja) 2001-05-24 2005-02-03 アレックザ モレキュラー デリヴァリー コーポレイション 所定の吸入ルートによる薬剤エステルの送出
ITMI20011445A1 (it) 2001-07-06 2003-01-06 Europ Geie Analoghi della cortistantina capaci di legarsi selettivamente ai recettori dei secretagoghi dell'ormone della crescita
US20030187076A1 (en) 2002-01-30 2003-10-02 Agoston Gregory E. Non-steroidal analogs of 2-methoxyestradiol
EP1575981B1 (en) 2002-12-24 2009-06-10 The University of British Columbia Angiogenic acting tri-sulphate steroids and uses thereof
ES2339450T3 (es) 2003-03-24 2010-05-20 Sterix Limited Derivados de estrogenos como inhibidores de esteroide sulfatasa.
JP2006526025A (ja) 2003-05-28 2006-11-16 エントレメッド インコーポレイテッド 抗血管新生剤
ATE460405T1 (de) * 2003-07-24 2010-03-15 Merck Sharp & Dohme Antibiotische verbindung
US20070004689A1 (en) 2004-03-12 2007-01-04 Agoston Gregory E Antiangiogenic agents
GB0421106D0 (en) 2004-09-22 2004-10-27 Sterix Ltd Compound
US7875599B2 (en) 2005-03-02 2011-01-25 University Of Maryland C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity
BRPI0706377A2 (pt) 2006-01-09 2011-03-22 Btg Int Ltd moduladores de fator -1 induzìvel por hipoxia e usos relacionados
WO2007082980A1 (es) 2006-01-23 2007-07-26 Consejo Superior De Investigaciones Científicas Composiciones y procedimientos para tratar trastornos inflamatorios e inmunitarios con cortistatina
WO2007103162A2 (en) 2006-03-01 2007-09-13 Samaritan Pharmaceuticals, Inc. Structure based drug design of steroidogenesis inhibitors
CN101443323A (zh) * 2006-05-09 2009-05-27 默克公司 取代的螺环cgrp受体拮抗剂
EP1870405A1 (en) * 2006-06-22 2007-12-26 Bioprojet Carbonylated (Aza)cyclohexanes as dopamine D3 receptor ligands
WO2008064425A1 (en) 2006-11-30 2008-06-05 Solbec Pharmaceuticals Limited Glycoalkaloid and chemotherapeutic agent combinations and various uses thereof
DK2114925T3 (da) 2006-12-22 2012-05-29 Ind Res Ltd Azetidin-analoger af nucleosidase- og phosphorylase-inhibitorer
WO2008109829A1 (en) 2007-03-07 2008-09-12 Infinity Pharmaceuticals, Inc. Cyclopamine lactam analogs and methods of use thereof
EP2205074A4 (en) * 2007-10-04 2013-07-31 Harvard College ANALOGUES OF THE MOENOMYCIN, METHODS OF SYNTHESIS AND USES THEREOF
CA2723689C (en) * 2008-05-05 2016-07-05 Ryan A. Shenvi Synthesis of (+) cortistatin a and related compounds
EP2334686B1 (en) 2008-08-28 2019-02-27 President and Fellows of Harvard College Cortistatin analogues and syntheses therof
WO2010123545A2 (en) 2009-04-22 2010-10-28 President And Fellows Of Harvard College Angiogenesis inhibitors
US8598344B2 (en) 2009-11-30 2013-12-03 Senex Biotechnology CDKI pathway inhibitors and uses thereof
CN103003281A (zh) 2010-05-20 2013-03-27 弗·哈夫曼-拉罗切有限公司 作为JAK和SYK抑制剂的吡咯并[2，3-b]吡嗪-7-甲酰胺衍生物和它们的用途
WO2012036287A1 (ja) 2010-09-17 2012-03-22 国立大学法人大阪大学 新規コルチスタチンａ類似体およびその用途
WO2012096934A2 (en) 2011-01-10 2012-07-19 The Scripps Research Institute Inhibitors of retroviral replication
UA117342C2 (uk) 2012-02-02 2018-07-25 Сенекс Біотекнолоджи Інк. Селективні інгібітори cdk8/cdk19 та їх застосування як протиметастатичних та хіміопрофілактичних засобів у способах лікування раку
WO2013122609A1 (en) 2012-02-17 2013-08-22 Genentech, Inc. Methods of using cdk8 antagonists
WO2014123900A1 (en) 2013-02-05 2014-08-14 Sirenas Marine Discovery Anti-cancer and anti-hiv compounds
US20160000787A1 (en) 2013-02-26 2016-01-07 Senex Biotechnology, Inc. Inhibitors of cdk8/19 for use in treating estrogen receptor positive breast cancer
EP3007686A4 (en) 2013-06-10 2017-03-15 Yeda Research and Development Co., Ltd. Compositions and methods for treating a hematological malignancy associated with an altered runx1 activity or expression
MY185593A (en) 2013-09-18 2021-05-24 Bcn Peptides Sa Cortistatin analogues for the treatment of inflammatory and/or immune diseases
PE20161405A1 (es) 2013-12-24 2017-01-18 Harvard College Analogos de cortistatina y sintesis y usos de los mismos

Also Published As

Publication number Publication date
EP3087080B1 (en) 2018-11-28
RU2016126503A3 (pt) 2018-07-17
US9994582B2 (en) 2018-06-12
EP3087080A1 (en) 2016-11-02
EA030907B1 (ru) 2018-10-31
ECSP16062174A (es) 2018-12-31
US10508121B2 (en) 2019-12-17
NI201600089A (es) 2016-08-18
EP3505521A1 (en) 2019-07-03
CL2016001631A1 (es) 2017-02-24
MX361652B (es) 2018-12-13
RU2016126503A (ru) 2018-01-30
WO2015100420A1 (en) 2015-07-02
TN2016000240A1 (en) 2017-10-06
MX2016008436A (es) 2016-12-16
SG11201605178WA (en) 2016-07-28
DOP2016000158A (es) 2016-10-16
SG10201808151RA (en) 2018-10-30
MD20160089A2 (ro) 2016-12-31
US20190185484A1 (en) 2019-06-20
CN106103452B (zh) 2019-05-21
JP2019108367A (ja) 2019-07-04
SA516371410B1 (ar) 2019-02-13
US20180319814A1 (en) 2018-11-08
AU2019201888A1 (en) 2019-04-11
PE20161405A1 (es) 2017-01-18
US10273241B2 (en) 2019-04-30
JP6494631B2 (ja) 2019-04-03
GT201600135A (es) 2018-11-27
CN110183461A (zh) 2019-08-30
KR20160101162A (ko) 2016-08-24
EA201691167A1 (ru) 2016-11-30
CR20160291A (es) 2017-02-24
SV2016005234A (es) 2018-12-14
JP2017509586A (ja) 2017-04-06
CN106103452A (zh) 2016-11-09
US20170029435A1 (en) 2017-02-02
AU2014369834A1 (en) 2016-06-23
ZA201603894B (en) 2018-08-29
MY180383A (en) 2020-11-28
AU2014369834B2 (en) 2018-12-20
PH12016501258A1 (en) 2016-08-15
EA201891279A1 (ru) 2019-01-31
AP2016009324A0 (en) 2016-07-31
IL246390A0 (en) 2016-08-31
ES2709480T3 (es) 2019-04-16
CA2934819A1 (en) 2015-07-02

Similar Documents

Publication Publication Date Title
BR112016014760A2 (pt) composto, composição farmacêutica, métodos para tratamento de uma condição, para inibir e validar atividade de cinase, para modular o trajeto de b-catenina e o trajeto de tgfb/bmp em uma célula, para modular a atividade de stat1 e de hif-1-alfa em uma célula, para aumentar a expressão de bim e para preparar um composto, mutante, e, proteína
BR112018070859A2 (pt) degradantes da proteína de bet
BR112018015273A2 (pt) derivados de benzimidazol como moduladores de ror-gama
BR112015021549A2 (pt) inibidores de piridina cinase cdk9
BR112016016844A2 (pt) Compostos heterocíclicos
BR112015022993A2 (pt) inibidores de jak2 e alk2 e métodos de uso dos mesmos
BR112015001419A8 (pt) composto, composição farmacêutica, e, uso de um composto ou de um sal farmaceuticamente aceitável do mesmo
BR112017007662A8 (pt) Composto, composição farmacêutica e uso de um composto
BR112015028501A2 (pt) derivados de bipirazol como inibidores de jak
BR112016008849B8 (pt) Compostos ou sais farmaceuticamente aceitáveis dos mesmos, uso dos referidos compostos e composições farmacêuticas
BR112017007460A2 (pt) inibidores de di-hidropirrolopiridina de ror-gama
BR112015001528A2 (pt) Composto, composição farmacêutica, e, uso de um composto ou de uma composição farmacêutica
BR112016028818A2 (pt) composição farmacêutica, métodos de tratamento de uma doença ou condição, de inibição da atividade de um polipeptídeo de fosfatidilinositol 3-quinase e de inibição de reações imunes excessivas ou destrutivas ou crescimento ou proliferação de células cancerosas, kit, composto, sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo, e, uso de um composto, um sal, isômero, ou uma mistura farmaceuticamente aceitável do mesmo.
BR112012018695A2 (pt) compostos pirazol como antagonistas crth2
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112017023147A2 (pt) azabenzimidazóis e seu uso como moduladores do receptor de ampa
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112017023038A2 (pt) imidazopirazinas e pirazolopirimidinas e seu uso como moduladores do receptor ampa
BR112013026397A2 (pt) Compostos cromenona como inibidores de pi 3-cinase para o tratamento de câncer
BR112017016817A2 (pt) derivados heterocíclicos formilados como inibidores de fgfr4
BR112013019160A2 (pt) novos compostos, composição farmacêutica, uso, processos e métodos
BR112017009012A2 (pt) derivados de anel benzo de seis membros como inibidor de dpp-4 e seu uso
BR112015022758A2 (pt) derivados de pirrolidina, composições farmacêuticas contendo os mesmos e seu uso em terapia
BR112019024322A2 (pt) Compostos e composições terapêuticos e métodos de uso dos mesmos
BR112015023356A2 (pt) inibidores de quinase pirrol[2,3-b]piridina cdk9

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A ANUIDADE.

B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements
B350 Update of information on the portal [chapter 15.35 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]